口服阿扎胞苷可延长缓解期急性髓系白血病患者的生存期,且与可测量残留病灶状态无关
在3期QUAZAR AML-001试验中,口服阿扎胞苷(口服-AZA)对比安慰剂可显著延长≥55岁、强化化疗后首次缓解且不适合造血干细胞移植的急性髓系白血病(AML)患者的总生存期和无复发生存期,且该获益独立于基线可测量残留病灶(MRD)状态。口服-AZA还使MRD阴性持续时间延长6个月,并使基线MRD阳性转为MRD阴性的比例更高(37% vs 19%)。
要点
- 口服阿扎胞苷对比安慰剂显著改善总生存期和无复发生存期,且独立于基线MRD状态。
- 口服阿扎胞苷使MRD阴性持续时间较安慰剂延长6个月。
- 基线MRD阳性转为MRD阴性的比例:口服阿扎胞苷组37% vs 安慰剂组19%。
核心结论
- 在强化化疗后首次缓解、不适合造血干细胞移植的≥55岁AML患者中,口服阿扎胞苷维持治疗对比安慰剂可显著延长总生存期和无复发生存期,且该获益独立于基线MRD状态。
- 口服阿扎胞苷组基线MRD阳性转为MRD阴性的比例为37%,安慰剂组为19%。
- 口服阿扎胞苷组中24%的MRD应答者在治疗开始后超过6个月达到MRD阴性。
研究设计与样本
- 3期QUAZAR AML-001试验(clinicaltrials.gov注册号NCT01757535)。
- 研究对象为≥55岁、强化化疗后首次缓解、不适合造血干细胞移植的AML患者。
- MRD定义为骨髓中白血病细胞≥0.1%,采用多参数流式细胞术在基线和每3个周期第1天采集的连续样本中评估。
主要发现
- 基线MRD状态与总生存期和无复发生存期均显著相关。
- 多因素分析显示,口服阿扎胞苷对比安慰剂显著改善总生存期和无复发生存期,且独立于基线MRD状态。
- 口服阿扎胞苷对比安慰剂使MRD阴性持续时间延长6个月。
- 口服阿扎胞苷组中24%的MRD应答者在治疗开始后超过6个月达到MRD阴性。
关键数值与推荐
- MRD阳性定义为骨髓中白血病细胞≥0.1%。
- MRD评估时间点为基线和每3个周期第1天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy is predictive of early relapse and poor survival. Postremission maintenance therapy that prolongs MRD negativity or converts MRD+ patients to MRD- status may delay or prevent relapse and improve overall survival (OS). In the phase 3 QUAZAR AML-001 trial, oral azacitidine (oral-AZA; formerly CC-486), a hypomethylating agent, significantly prolonged OS and relapse-free survival (RFS) compared with placebo in patients aged ≥55 years with AML in first remission after intensive chemotherapy who were not candidates for hematopoietic stem cell transplantation. In this trial, MRD (≥0.1% leukemic cells in bone marrow) was assessed by multiparameter flow cytometry in serial samples collected at baseline and on day 1 of every 3 cycles. As expected, baseline MRD status was significantly associated with both OS and RFS. Multivariate analyses showed oral-AZA significantly improved OS and RFS vs placebo independent of baseline MRD status. Oral-AZA treatment also extended the duration of MRD negativity by 6 months vs placebo and resulted in a higher rate of conversion from MRD+ at baseline to MRD- during treatment: 37% vs 19%, respectively. In the oral-AZA arm, 24% of MRD responders achieved MRD negativity >6 months after treatment initiation. Although presence or absence of MRD was a strong prognostic indicator of OS and RFS, there were added survival benefits with oral-AZA maintenance therapy compared with placebo, independent of patients' MRD status at baseline. Registered at clinicaltrials.gov as #NCT01757535.
引用
- Roboz GJ, Ravandi F, Wei AH, et al. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood. 2022. PMID: 34995344. doi:10.1182/blood.2021013404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。